Literature DB >> 3987174

Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.

N M Woolhouse, M Eichelbaum, N S Oates, J R Idle, R L Smith.   

Abstract

The ability to oxidize sparteine to form 2- and 5-dehydrosparteine was studied in 154 healthy Ghanaians. Although the urinary metabolic sparteine/dehydrosparteines ratio varied widely (from 0.14 to 12.5), in contrast to observations in several Caucasian population groups the ratios were not bimodally distributed and no phenotypically poor oxidizers of sparteine were found. The ability of these same subjects to oxidize debrisoquin and phenformin was also studied in 141 and 143 subjects. Of the 141 subjects dosed with debrisoquin, 10 proved to be poor oxidizers, and of the 143 subjects dosed with phenformin, 11 were poor oxidizers. All the poor oxidizers of debrisoquin were also poor oxidizers of phenformin. The 10 confirmed poor metabolizers of debrisoquin, who had debrisoquin metabolic ratios ranging from 14.4 to 52.0, had sparteine metabolic ratios ranging only from 0.15 to 12.5. Whereas Caucasian poor metabolizers of sparteine excrete less than 2.0% of a dose as dehydrosparteines, the mean excretion of dehydrosparteines in our 10 subjects was 20.6% +/- 13.2%. The overall rank correlation between the sparteine and debrisoquin metabolic ratios was low (rs = 0.47), while the coefficient of determination for linear regression (r2) was only 0.17. Our data show that the ability of Ghanaians to oxidize sparteine is largely independent of their capacity for debrisoquin oxidation and is indicative of a major interethnic difference in the genetic control of these reactions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987174     DOI: 10.1038/clpt.1985.81

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Uses and misuses of definitions of genetic polymorphism. A perspective from population pharmacogenetics.

Authors:  T D Arias; L F Jorge; R Barrantes
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 3.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.

Authors:  Y Horai; J Taga; T Ishizaki; K Ishikawa
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 5.  Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs.

Authors:  P A De Smet; J R Brouwers
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

6.  Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.

Authors:  A Bozkurt; N E Basçi; A Işimer; A Sayal; S O Kayaalp
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

7.  Evidence for polymorphic oxidation of sparteine in Japanese subjects.

Authors:  T Ishizaki; M Eichelbaum; Y Horai; K Hashimoto; K Chiba; H J Dengler
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

8.  Oxidative polymorphism of dextromethorphan in a Burundi population.

Authors:  F Nsabiyumva; Y Furet; E Autret; A P Jonville; M Breteau
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Debrisoquine oxidation polymorphism in a Tasmanian population.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.

Authors:  N E Basci; K Brosen; A Bozkurt; A Isimer; A Sayal; S O Kayaalp
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.